AU2013404949B2 - Methods for inhibiting TIE2 kinase useful in the treatment of cancer - Google Patents

Methods for inhibiting TIE2 kinase useful in the treatment of cancer Download PDF

Info

Publication number
AU2013404949B2
AU2013404949B2 AU2013404949A AU2013404949A AU2013404949B2 AU 2013404949 B2 AU2013404949 B2 AU 2013404949B2 AU 2013404949 A AU2013404949 A AU 2013404949A AU 2013404949 A AU2013404949 A AU 2013404949A AU 2013404949 B2 AU2013404949 B2 AU 2013404949B2
Authority
AU
Australia
Prior art keywords
formula
composition
leu
combination
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013404949A
Other languages
English (en)
Other versions
AU2013404949A1 (en
Inventor
Daniel L. Flynn
Michael D. Kaufman
Marc S. RUDOLTZ
Bryan Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of AU2013404949A1 publication Critical patent/AU2013404949A1/en
Application granted granted Critical
Publication of AU2013404949B2 publication Critical patent/AU2013404949B2/en
Priority to AU2019200261A priority Critical patent/AU2019200261A1/en
Priority to AU2021200113A priority patent/AU2021200113A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013404949A 2013-11-07 2013-11-07 Methods for inhibiting TIE2 kinase useful in the treatment of cancer Active AU2013404949B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019200261A AU2019200261A1 (en) 2013-11-07 2019-01-15 Methods for inhibiting tie2 kinase useful in the treatment of cancer
AU2021200113A AU2021200113A1 (en) 2013-11-07 2021-01-10 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/069005 WO2015069266A1 (en) 2013-11-07 2013-11-07 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200261A Division AU2019200261A1 (en) 2013-11-07 2019-01-15 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2013404949A1 AU2013404949A1 (en) 2016-05-26
AU2013404949B2 true AU2013404949B2 (en) 2018-10-18

Family

ID=53041876

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013404949A Active AU2013404949B2 (en) 2013-11-07 2013-11-07 Methods for inhibiting TIE2 kinase useful in the treatment of cancer
AU2019200261A Abandoned AU2019200261A1 (en) 2013-11-07 2019-01-15 Methods for inhibiting tie2 kinase useful in the treatment of cancer
AU2021200113A Pending AU2021200113A1 (en) 2013-11-07 2021-01-10 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019200261A Abandoned AU2019200261A1 (en) 2013-11-07 2019-01-15 Methods for inhibiting tie2 kinase useful in the treatment of cancer
AU2021200113A Pending AU2021200113A1 (en) 2013-11-07 2021-01-10 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Country Status (7)

Country Link
EP (1) EP3065549A4 (ko)
JP (1) JP6568093B2 (ko)
KR (2) KR20160070188A (ko)
CN (2) CN105873440B (ko)
AU (3) AU2013404949B2 (ko)
CA (1) CA2929715A1 (ko)
WO (1) WO2015069266A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
WO2016191401A1 (en) * 2015-05-27 2016-12-01 Albert Einstein College Of Medicine, Inc. Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106822128A (zh) * 2017-02-24 2017-06-13 南华大学附属第医院 酪氨酸激酶抑制剂dcc‑2036的新应用
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
TW202122085A (zh) * 2019-08-12 2021-06-16 美商迪賽孚爾製藥公司 治療血管畸形之方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
WO2011150198A1 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2012097021A1 (en) * 2011-01-11 2012-07-19 Glaxosmithkline Llc Combination
MX359664B (es) * 2011-07-29 2018-10-05 Univ Colorado Regents Tratamiento de cáncer de mama.
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Smith, B. D. et al. Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model" Cancer Res 2013, Vol. 73(3 Suppl):Abstract nr B78. *

Also Published As

Publication number Publication date
AU2019200261A1 (en) 2019-01-31
KR20210063475A (ko) 2021-06-01
KR20160070188A (ko) 2016-06-17
WO2015069266A1 (en) 2015-05-14
EP3065549A4 (en) 2017-05-24
CN105873440B (zh) 2018-06-01
JP6568093B2 (ja) 2019-08-28
CN105873440A (zh) 2016-08-17
JP2017500371A (ja) 2017-01-05
CN108464981A (zh) 2018-08-31
AU2013404949A1 (en) 2016-05-26
CA2929715A1 (en) 2015-05-14
EP3065549A1 (en) 2016-09-14
AU2021200113A1 (en) 2021-03-04
CN108464981B (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
AU2013404949B2 (en) Methods for inhibiting TIE2 kinase useful in the treatment of cancer
US20190091217A1 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
KR20170001962A (ko) 항 악성 종양제 조성물
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
KR20180030630A (ko) 아필리모드를 이용한 암 치료 방법
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
TW202003553A (zh) 用於治療癌症之abbv-621與抗癌劑之組合
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP7420402B2 (ja) 免疫チェックポイント分子の発現抑制剤
US20220047573A1 (en) Methods for treating vascular malformations
US20150306216A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP2017512768A (ja) Ｅｒｇ発癌遺伝子陽性癌のための新規阻害剤
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
US12016862B2 (en) Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
WO2021030404A1 (en) Methods and compositions for treating vascular malformations
WO2023172643A1 (en) The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
CA3065574A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
Koch The role of MYD88-dependent receptors in the anti-tumor efficacy of the EGFR inhibitor Erlotinib in head and neck cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)